Age-related macular degeneration (AMD) is a leading cause of visual impairment in the United States. Although no therapies are approved to treat the dry form of the disease, the standard of care…
Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…
Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…
MARKET OUTLOOK Two of the largest U.S. pharmacy benefit managers, Express Scripts and CVS Health, set in motion a new approach to drug reimbursement by introducing indication-specific pricing (ISP…
Market Outlook Carbapenem-resistant organisms (CROs) are responsible for difficult-to-treat, life-threatening gram-negative infections that require hospitalization. Of the currently marketed…
Market Outlook Carbapenem-resistant organisms (CROs) are responsible for difficult-to-treat, life-threatening gram-negative infections that require hospitalization. Of the currently marketed…
The systemic lupus erythematosus (SLE) market in the United States is largely genericized and off-label. With the exception of Benlysta (IV)—which launched in 2011—no new drug has been approved…
Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs). It is characterized by an irreversible loss of lung function, leading to…
Immune thrombocytopenic purpura (ITP) is a hematological autoimmune disorder characterized by low platelet count in the blood, which may lead to easy bruising and bleeding. ITP has an acute,…
Treatment of heart failure with reduced ejection fraction (HFrEF) is well-established with a wealth of evidence from clinical trials that support the use of all standard-of-care therapies for CHF…
Beta thalassemia is a rare genetic blood disorder characterized by a substantial reduction in or lack of β-globin protein and resulting in chronic anemia, failure to thrive, jaundice, pallor, poor…
IL-17 inhibitors have set a new efficacy standard in moderate to severe psoriasis, putting pressure on the more established TNF-α inhibitors and the IL-12/23 inhibitor Stelara. Although IL-17…
MARKET OUTLOOK The treatment of Crohn’s disease (CD) includes not only conventional therapies, many of which are generically available, but also potent biologics, which are often reserved for…
MARKET OUTLOOK The treatment of Crohn’s disease (CD) includes not only conventional therapies, many of which are generically available, but also potent biologics, which are often reserved for…
MARKET OUTLOOK Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with these agents,…
